NASDAQ:GLMD Galmed Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Galmed Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. $0.62 -0.03 (-5.35%) (As of 07/1/2022 08:44 PM ET) Add Compare Share Today's Range$0.59▼$0.7050-Day Range$0.44▼$1.6652-Week Range$0.42▼$3.42Volume40,700 shsAverage Volume109,060 shsMarket Capitalization$15.43 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Galmed Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside712.7% Upside$5.00 Price TargetShort InterestHealthy0.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.22Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.85) to ($0.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.51 out of 5 starsMedical Sector982nd out of 1,412 stocksPharmaceutical Preparations Industry482nd out of 673 stocks 3.0 Analyst's Opinion Consensus RatingGalmed Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, Galmed Pharmaceuticals has a forecasted upside of 712.7% from its current price of $0.62.Amount of Analyst CoverageGalmed Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.50% of the float of Galmed Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverGalmed Pharmaceuticals has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Galmed Pharmaceuticals has recently increased by 364.50%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGalmed Pharmaceuticals does not currently pay a dividend.Dividend GrowthGalmed Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GLMD. Previous Next 1.8 News and Social Media Coverage News SentimentGalmed Pharmaceuticals has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Galmed Pharmaceuticals this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for GLMD on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Galmed Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Galmed Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 13.37% of the stock of Galmed Pharmaceuticals is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Galmed Pharmaceuticals are expected to grow in the coming year, from ($0.85) to ($0.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Galmed Pharmaceuticals is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Galmed Pharmaceuticals is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGalmed Pharmaceuticals has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GLMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address About Galmed Pharmaceuticals (NASDAQ:GLMD) StockGalmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.Read More GLMD Stock News HeadlinesJuly 3, 2022 | americanbankingnews.comGalmed Pharmaceuticals (NASDAQ:GLMD) & Cerevel Therapeutics (NASDAQ:CERE) Head-To-Head ContrastJune 30, 2022 | americanbankingnews.comGalmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated by Analysts at StockNews.comJune 17, 2022 | finance.yahoo.comGalmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price NotificationJune 14, 2022 | americanbankingnews.comGalmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by StockNews.comJune 10, 2022 | americanbankingnews.comGalmed Pharmaceuticals Ltd. Expected to Earn FY2023 Earnings of ($0.35) Per Share (NASDAQ:GLMD)May 25, 2022 | benzinga.comGalmed Pharmaceuticals (NASDAQ:GLMD), Analyst Ratings, Price Targets, PredictionsMay 18, 2022 | seekingalpha.comGalmed Pharmaceuticals shares fall after downgrade by Raymond James analystMay 17, 2022 | finance.yahoo.comGalmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effectsMay 17, 2022 | finance.yahoo.comGalmed Pharmaceuticals Reports First Quarter 2022 Financial ResultsMay 3, 2022 | marketwatch.comGalmed Pharmaceuticals Shares Down 16%May 3, 2022 | markets.businessinsider.comRaymond James Maintains Outperform Rating for Galmed Pharmaceuticals: Here's What You Need To KnowMay 2, 2022 | seekingalpha.comGalmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q4 2021 Results - Earnings Call TranscriptMay 2, 2022 | finance.yahoo.comGalmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial ResultsApril 29, 2022 | benzinga.comGalmed Pharmaceuticals's Earnings OutlookApril 28, 2022 | finance.yahoo.comGalmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessmentApril 26, 2022 | finance.yahoo.comGalmed Pharmaceuticals to Report Fourth Quarter and Year End 2021 Financial Results and Provide Business Update on Monday May 2January 11, 2022 | seekingalpha.comGalmed gains 5% after securing three new U.S. patents for Aramchol and meglumine saltJanuary 11, 2022 | nasdaq.comGalmed Pharmaceuticals Ltd Shares Fall 5.2% Below Previous 52-Week Low - Market MoverJanuary 11, 2022 | finance.yahoo.comGalmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine SaltJanuary 10, 2022 | finance.yahoo.comGalmed's Potential Ulcerative Colitis Candidate Shows Encouraging Action In Early StudyNovember 11, 2021 | nasdaq.comHere's Why We're Watching Galmed Pharmaceuticals' (NASDAQ:GLMD) Cash Burn SituationNovember 8, 2021 | finance.yahoo.comGalmed Announces New Positive Data from Ongoing ARMOR Study Open Label Part Showing Clinically Significant Effect on Fibrosis ImprovementNovember 8, 2021 | finance.yahoo.comGalmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial ResultsNovember 1, 2021 | finance.yahoo.comGalmed Reveals Early Aramchol Data From Late-Stage NASH TrialNovember 1, 2021 | finance.yahoo.comGalmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR StudySee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GLMD CUSIPN/A CIK1595353 Webwww.galmedpharma.com Phone(723) 693-8448Fax972-3693-8447Employees18Year FoundedN/ACompany Calendar Last Earnings5/17/2022Today7/04/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$5.00 High Stock Price Forecast$5.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+712.7%Consensus RatingHold Rating Score (0-4)2 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.180010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32.47 million Net MarginsN/A Pretax MarginN/A Return on Equity-86.53% Return on Assets-72.82% Debt Debt-to-Equity Ratio0.01 Current Ratio5.26 Quick Ratio5.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.22 per share Price / Book0.50Miscellaneous Outstanding Shares25,088,000Free FloatN/AMarket Cap$15.43 million OptionableOptionable Beta1.53 Galmed Pharmaceuticals Frequently Asked Questions Should I buy or sell Galmed Pharmaceuticals stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Galmed Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLMD, but not buy additional shares or sell existing shares. View analyst ratings for Galmed Pharmaceuticals or view top-rated stocks. What is Galmed Pharmaceuticals' stock price forecast for 2022? 2 equities research analysts have issued 12 month price targets for Galmed Pharmaceuticals' stock. Their GLMD stock forecasts range from $5.00 to $5.00. On average, they anticipate Galmed Pharmaceuticals' share price to reach $5.00 in the next twelve months. This suggests a possible upside of 712.7% from the stock's current price. View analysts' price targets for Galmed Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has Galmed Pharmaceuticals' stock performed in 2022? Galmed Pharmaceuticals' stock was trading at $1.82 on January 1st, 2022. Since then, GLMD stock has decreased by 66.2% and is now trading at $0.6152. View the best growth stocks for 2022 here. When is Galmed Pharmaceuticals' next earnings date? Galmed Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Galmed Pharmaceuticals. How were Galmed Pharmaceuticals' earnings last quarter? Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) issued its earnings results on Tuesday, May, 17th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.09. View Galmed Pharmaceuticals' earnings history. Who are Galmed Pharmaceuticals' key executives? Galmed Pharmaceuticals' management team includes the following people: Mr. Allen Baharaff, Co-Founder, Pres, CEO & Chairman (Age 57, Pay $1.71M)Mr. Guy Nehemya, COO & Data Protection Officer (Age 37, Pay $168.93k)Mr. Yohai Stenzler CPA, Chief Accounting Officer (Age 39, Pay $173.11k)Dr. Liat Hayardeny, Chief Scientific Officer (Age 55, Pay $263.01k)Mr. Doron Cohen, Chief Financial Officer (Age 55)Ms. Yael Hollander, VP of Legal Affairs & Strategy (Age 39)Ms. Shani Ganon, HR Mang.Dr. Tali Gorfine, Medical Consultant (Age 52)Mr. Niv Alon, Head of PMOMs. Topaz Falkoviz Arbel, Corp. Sec. Who are some of Galmed Pharmaceuticals' key competitors? Some companies that are related to Galmed Pharmaceuticals include SCYNEXIS (SCYX), Lantern Pharma (LTRN), Mustang Bio (MBIO), BeyondSpring (BYSI), Opiant Pharmaceuticals (OPNT), DiaMedica Therapeutics (DMCAF), Verrica Pharmaceuticals (VRCA), Avalo Therapeutics (AVTX), 9 Meters Biopharma (NMTR), Syros Pharmaceuticals (SYRS), Orgenesis (ORGS), Oncolytics Biotech (ONCY), LifeVantage (LFVN), iBio (IBIO) and Catalyst Biosciences (CBIO). View all of GLMD's competitors. What other stocks do shareholders of Galmed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include OPKO Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rite Aid (RAD), Exelixis (EXEL), Ocular Therapeutix (OCUL), TG Therapeutics (TGTX), TherapeuticsMD (TXMD) and Corbus Pharmaceuticals (CRBP). What is Galmed Pharmaceuticals' stock symbol? Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD." How do I buy shares of Galmed Pharmaceuticals? Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Galmed Pharmaceuticals' stock price today? One share of GLMD stock can currently be purchased for approximately $0.62. How much money does Galmed Pharmaceuticals make? Galmed Pharmaceuticals (NASDAQ:GLMD) has a market capitalization of $15.43 million. The biopharmaceutical company earns $-32.47 million in net income (profit) each year or ($1.180010) on an earnings per share basis. How many employees does Galmed Pharmaceuticals have? Galmed Pharmaceuticals employs 18 workers across the globe. How can I contact Galmed Pharmaceuticals? Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The official website for Galmed Pharmaceuticals is www.galmedpharma.com. The biopharmaceutical company can be reached via phone at (723) 693-8448, via email at investor.relations@galmedpharma.com, or via fax at 972-3693-8447. This page (NASDAQ:GLMD) was last updated on 7/4/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
